TNF and inflammatory bowel disease: Recently, biologic agents targeting tumour necrosis factor-alpha (TNFα), adhesion molecules, and the p40 subunit of interleukin (IL)-12/23 have emerged to revolutionise the treatment of IBD (Yanai and Hanauer, 2011; Feagan et al., 2013; Sands et al., 2019a).